Developer docs
API playgroundTry for free, no card

Search company profiles

BiomEdit

Full company profile

uuid0000cy5

Namestring
BiomEdit
Legal namestring
BiomEdit LLC
Websiteurl
biomedit.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

BiomEdit is an animal health biotechnology company that discovers, designs, and develops microbiome-derived products for livestock, poultry, aquaculture, and companion animals. The company operates an integrated platform combining microbiome discovery (high-throughput sequencing and 'omics'), synthetic biology (engineered Lactobacillus reuteri strains enabling localized payload expression), and explainable AI-powered predictive algorithms that improve candidate selection success rates relative to traditional screening methods. Its lead product, BE-101 (to be commercialized under the brand Optavant), is a bacterial-vectored antibody fragment targeting Clostridium perfringens toxins in broiler chickens to prevent necrotic enteritis, with USDA conditional licensure anticipated in Q3 2026 and commercial launch planned for early Q4 2026.

The pipeline extends beyond BE-101 to include BE-102 (Campylobacter jejuni), BE-106 (vectored Eimeria vaccine), BE-01 and BE-02 (livestock gut health), BE-07 (aquaculture probiotics), and BE-105 (feline metabolic disease), supported by 73 patents and 450+ peer-reviewed publications across the team. The business model is B2B enterprise field sales to large commercial poultry and livestock producers, supplemented by a long-term commercial partnership with Nutreco for next-generation ultra-specialty feed additives (Biome-actives). Revenue is not yet generated, and the company is funded through $55.4M in equity ($37M Series A in January 2023, $18.4M Series B in July 2025 led by Anterra Capital) and approximately $6.5M in grants from the Bill and Melinda Gates Foundation and the Bezos Earth Fund.

Short descriptiontext

BiomEdit is a microbiome biotechnology company developing engineered probiotic products for animal health, with a lead poultry biologic (BE-101/Optavant) targeting necrotic enteritis in broiler chickens and a broader pipeline spanning livestock, aquaculture, and companion animals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGreenfield, United States
HQ citystring
Greenfield
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbiome animal health, engineered probiotics, poultry biologics, feed additives, methane reduction
Industry6 codes
PRIMARYHLAAAFAL
Non-Human Microbiome Therapeutics (veterinary/animal microbiome interventions)
SECONDARYHLAMAHAH
Nutraceuticals & Functional Ingredients for Animal Diets (Probiotics, Omega-3, Joint, GI)
Healthcare & Life Sciences/Veterinary & Animal Health/Animal Nutrition & Therapeutic Diets
SECONDARYAFADALAE
Probiotics, Prebiotics & Postbiotics (Direct-Fed Microbials)
SECONDARYAFADAKAC
Probiotics, Prebiotics & Synbiotics
Agriculture & Food Production/Animal Feed Manufacturing/Medicated & Functional Feed (Coccidiostats, Probiotics, Performance Additives)
SECONDARYHLAAAFAG
Microbiome Modulating Small Molecules & Antibiotic Alternatives
SECONDARYHLAMAEAE
Antimicrobials & Anti-infectives
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Other Animal Food Manufacturing311119
  • Animal Food Manufacturing3111
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Agricultural Prod-Livestock & Animal Specialties200
Product category
Animal Health Biologics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Biologics (Animal Health)
TypeOne Time License
Description

Non-antibiotic poultry biologic products (BE-101) sold to commercial broiler producers for disease prevention and performance enhancement. Commercial launch planned for Q4 2026.

biomedit.com
2Feed Additives (Foundational Products)
TypeOne Time License
Description

Next-generation and ultra-specialty feed additives developed for food animals including livestock and aquaculture, providing novel features that support animal health and growth.

biomedit.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Optavant
Description

Brand name under which BE-101 non-antibiotic poultry biologic will be commercialized for poultry health.

prnewswire.com
Core offering1 text field

BiomEdit discovers, designs, and develops novel microbiome-derived products for animal health, including engineered probiotic biologics (e.g., BE-101 targeting necrotic enteritis in poultry, marketed as Optavant), next-generation feed additives (Biome-actives), and methane-reduction products for cattle. The company combines microbiome discovery, synthetic biology, and explainable AI to create non-antibiotic solutions for poultry, livestock, aquaculture, and pet health markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • BE-101 demonstrated efficacy in improving feed conversion, weight gain, and reducing mortality caused by necrotic enteritis in broiler chickens
+1 more record
Product and service2 records
1BE-101 (Optavant)
CategoryPoultry Biologics
2BE-102
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-10-01
Description

Collaboration announced October 2023 to develop sustainability protocols in methane-reducing products, as well as AMR and food safety risk reduction projects.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-08-01
Description

Integrated drug discovery collaboration announced August 2023.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-10-01
Description

Research collaboration announced October 2022 to increase sustainability of shrimp farming and improve global food security.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global animal health leader and the original parent of BiomEdit's microbiome platform (carved out in 2022). Directly comparable as a broad animal-health incumbent with overlapping interests in livestock, poultry, and pet health; Elanco's existing vaccine and feed-additive portfolios compete with BiomEdit's pipeline.

TypeBroad incumbent
Description

Largest pure-play animal health company globally, with biologics, vaccines, and feed-additive products across poultry, livestock, and companion animals. Directly competes with BiomEdit's poultry biologic BE-101 and livestock probiotic programs through established producer relationships.

TypeBroad incumbent
Description

Division of Merck & Co. offering vaccines, anti-infectives, and animal health products; competes in the same necrotic enteritis and poultry-health markets as BiomEdit's BE-101. Comparable as a broad incumbent with R&D scale and global distribution.

TypeBroad incumbent
Description

Animal health and nutrition company with significant presence in poultry, swine, and cattle including medicated feed additives and nutritional specialty products; directly competes with BiomEdit's feed-additive and poultry-health offerings.

5Arm & Hammer Animal and Food Production
TypeDirect peer
Description

Business of Church & Dwight that develops direct-fed microbials, probiotics, and gut-health solutions for livestock and poultry producers. Closely comparable to BiomEdit's feed-additive (Biome-actives) and probiotic pipeline targeting similar producers.

TypeDirect peer
Description

Global bioscience company with a major animal health and nutrition segment offering probiotic and microbial solutions for poultry, swine, and aquaculture. Directly comparable to BiomEdit's engineered-probiotic platform and DFM feed-additive strategy.

TypeBroad incumbent
Description

Combined Novozymes/Novonesis is a global enzyme and microbial solutions provider with a strong animal-health and feed-additives business; overlaps with BiomEdit's enzyme-based BE-01 livestock product and broader microbial discovery platform.

TypeDirect peer
Description

Global ingredient manufacturer specializing in animal nutrition and health, including gut-health, immune, and antibiotic-alternative feed additives for poultry and livestock. Directly comparable to BiomEdit's feed-additive pipeline targeting the same antibiotic-free production trend.

TypeBroad incumbent
Description

Major animal nutrition and health player offering vitamins, eubiotics (including probiotics), and performance additives for livestock and aquaculture; broad incumbent competing with BiomEdit across multiple animal segments and especially relevant for methane-reduction work in cattle.

TypeBroad incumbent
Description

Global agribusiness with a large animal nutrition business selling premixes, additives, and feed solutions to livestock and poultry producers; broad incumbent that overlaps with BiomEdit's feed-additive strategy and has the scale to compete on pricing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BiomEdit

Animal Health Biologicsbiomedit.com

BiomEdit is a microbiome biotechnology company developing engineered probiotic products for animal health, with a lead poultry biologic (BE-101/Optavant) targeting necrotic enteritis in broiler chickens and a broader pipeline spanning livestock, aquaculture, and companion animals.

What BiomEdit does

BiomEdit is an animal health biotechnology company that discovers, designs, and develops microbiome-derived products for livestock, poultry, aquaculture, and companion animals. The company operates an integrated platform combining microbiome discovery (high-throughput sequencing and 'omics'), synthetic biology (engineered Lactobacillus reuteri strains enabling localized payload expression), and explainable AI-powered predictive algorithms that improve candidate selection success rates relative to traditional screening methods. Its lead product, BE-101 (to be commercialized under the brand Optavant), is a bacterial-vectored antibody fragment targeting Clostridium perfringens toxins in broiler chickens to prevent necrotic enteritis, with USDA conditional licensure anticipated in Q3 2026 and commercial launch planned for early Q4 2026.

The pipeline extends beyond BE-101 to include BE-102 (Campylobacter jejuni), BE-106 (vectored Eimeria vaccine), BE-01 and BE-02 (livestock gut health), BE-07 (aquaculture probiotics), and BE-105 (feline metabolic disease), supported by 73 patents and 450+ peer-reviewed publications across the team. The business model is B2B enterprise field sales to large commercial poultry and livestock producers, supplemented by a long-term commercial partnership with Nutreco for next-generation ultra-specialty feed additives (Biome-actives). Revenue is not yet generated, and the company is funded through $55.4M in equity ($37M Series A in January 2023, $18.4M Series B in July 2025 led by Anterra Capital) and approximately $6.5M in grants from the Bill and Melinda Gates Foundation and the Bezos Earth Fund.

BiomEdit firmographics

Firmographics
Name
BiomEdit
Legal name
BiomEdit LLC
Website
https://biomedit.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
BiomEdit is a microbiome biotechnology company developing engineered probiotic products for animal health, with a lead poultry biologic (BE-101/Optavant) targeting necrotic enteritis in broiler chickens and a broader pipeline spanning livestock, aquaculture, and companion animals.
Ownership category
akta.pro rank

BiomEdit industry classification

Industry
Product category
Animal Health Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Other Animal Food Manufacturing (311119), Animal Food Manufacturing (3111)
SIC
Biological Products, (No Disgnostic Substances) (2836), Agricultural Prod-Livestock & Animal Specialties (200)
akta.pro industry
PRIMARYHLAAAFAL
Non-Human Microbiome Therapeutics (veterinary/animal microbiome interventions)
SECONDARYHLAMAHAH
Nutraceuticals & Functional Ingredients for Animal Diets (Probiotics, Omega-3, Joint, GI)
Healthcare & Life Sciences/Veterinary & Animal Health/Animal Nutrition & Therapeutic Diets
SECONDARYAFADALAE
Probiotics, Prebiotics & Postbiotics (Direct-Fed Microbials)
SECONDARYAFADAKAC
Probiotics, Prebiotics & Synbiotics
Agriculture & Food Production/Animal Feed Manufacturing/Medicated & Functional Feed (Coccidiostats, Probiotics, Performance Additives)
SECONDARYHLAAAFAG
Microbiome Modulating Small Molecules & Antibiotic Alternatives
SECONDARYHLAMAEAE
Antimicrobials & Anti-infectives
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics

Keywords

  • Microbiome animal health
  • Engineered probiotics
  • Poultry biologics
  • Feed additives
  • Methane reduction

Where BiomEdit is headquartered

Location

Headquarters

HQ city
Greenfield
HQ country
United States
HQ region
North America

Offices2 records

Markets served

BiomEdit business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Biologics (Animal Health): Non-antibiotic poultry biologic products (BE-101) sold to commercial broiler producers for disease prevention and performance enhancement. Commercial launch planned for Q4 2026.
  2. Feed Additives (Foundational Products): Next-generation and ultra-specialty feed additives developed for food animals including livestock and aquaculture, providing novel features that support animal health and growth.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

BiomEdit product offering

Product offering

Core offering

BiomEdit discovers, designs, and develops novel microbiome-derived products for animal health, including engineered probiotic biologics (e.g., BE-101 targeting necrotic enteritis in poultry, marketed as Optavant), next-generation feed additives (Biome-actives), and methane-reduction products for cattle. The company combines microbiome discovery, synthetic biology, and explainable AI to create non-antibiotic solutions for poultry, livestock, aquaculture, and pet health markets.

Differentiator

Problem solved

Functional benefit

Brands

  • Optavant: Brand name under which BE-101 non-antibiotic poultry biologic will be commercialized for poultry health.

Products and services

  • BE-101 (Optavant)
  • BE-102

Quantifiable outcome

  • BE-101 demonstrated efficacy in improving feed conversion, weight gain, and reducing mortality caused by necrotic enteritis in broiler chickens
  • +1 more outcomes

Companies that use BiomEdit

Customer profile

Segments4 records

Ideal customer profiles4 records

BiomEdit technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

BiomEdit partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor.

  • AthianminorStrategic or Co-development Partner · 1 October 2023Collaboration announced October 2023 to develop sustainability protocols in methane-reducing products, as well as AMR and food safety risk reduction projects.
  • Indiana Biosciences Research InstituteminorStrategic or Co-development Partner · 1 August 2023Integrated drug discovery collaboration announced August 2023.
  • AtarrayaminorStrategic or Co-development Partner · 1 October 2022Research collaboration announced October 2022 to increase sustainability of shrimp farming and improve global food security.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

BiomEdit competitors and assessment

Company assessment

Broad incumbents

  • Elanco Animal Health: Global animal health leader and the original parent of BiomEdit's microbiome platform (carved out in 2022). Directly comparable as a broad animal-health incumbent with overlapping interests in livestock, poultry, and pet health; Elanco's existing vaccine and feed-additive portfolios compete with BiomEdit's pipeline.
  • Zoetis: Largest pure-play animal health company globally, with biologics, vaccines, and feed-additive products across poultry, livestock, and companion animals. Directly competes with BiomEdit's poultry biologic BE-101 and livestock probiotic programs through established producer relationships.
  • Merck Animal Health: Division of Merck & Co. offering vaccines, anti-infectives, and animal health products; competes in the same necrotic enteritis and poultry-health markets as BiomEdit's BE-101. Comparable as a broad incumbent with R&D scale and global distribution.
  • Phibro Animal Health: Animal health and nutrition company with significant presence in poultry, swine, and cattle including medicated feed additives and nutritional specialty products; directly competes with BiomEdit's feed-additive and poultry-health offerings.
  • Novozymes (Novonesis): Combined Novozymes/Novonesis is a global enzyme and microbial solutions provider with a strong animal-health and feed-additives business; overlaps with BiomEdit's enzyme-based BE-01 livestock product and broader microbial discovery platform.
  • dsm-firmenich Animal Nutrition & Health: Major animal nutrition and health player offering vitamins, eubiotics (including probiotics), and performance additives for livestock and aquaculture; broad incumbent competing with BiomEdit across multiple animal segments and especially relevant for methane-reduction work in cattle.
  • Cargill Animal Nutrition: Global agribusiness with a large animal nutrition business selling premixes, additives, and feed solutions to livestock and poultry producers; broad incumbent that overlaps with BiomEdit's feed-additive strategy and has the scale to compete on pricing.

Direct peers

  • Arm & Hammer Animal and Food Production: Business of Church & Dwight that develops direct-fed microbials, probiotics, and gut-health solutions for livestock and poultry producers. Closely comparable to BiomEdit's feed-additive (Biome-actives) and probiotic pipeline targeting similar producers.
  • Chr. Hansen: Global bioscience company with a major animal health and nutrition segment offering probiotic and microbial solutions for poultry, swine, and aquaculture. Directly comparable to BiomEdit's engineered-probiotic platform and DFM feed-additive strategy.
  • Kemin Industries: Global ingredient manufacturer specializing in animal nutrition and health, including gut-health, immune, and antibiotic-alternative feed additives for poultry and livestock. Directly comparable to BiomEdit's feed-additive pipeline targeting the same antibiotic-free production trend.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

BiomEdit social profiles

Digital presence

BiomEdit financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BiomEdit leadership team

Management profile

Number of profiles

Profiles9 records

BiomEdit funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BiomEdit M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BiomEdit

What does BiomEdit do?

BiomEdit discovers, designs, and develops novel microbiome-derived products for animal health, including engineered probiotic biologics (e.g., BE-101 targeting necrotic enteritis in poultry, marketed as Optavant), next-generation feed additives (Biome-actives), and methane-reduction products for cattle. The company combines microbiome discovery, synthetic biology, and explainable AI to create non-antibiotic solutions for poultry, livestock, aquaculture, and pet health markets.

Is BiomEdit a public or private company?

BiomEdit is a private company. It is classified as venture growth investor backed and is currently operating.

When was BiomEdit founded?

BiomEdit was founded in 2022. It employs 11 to 50 people.

Where is BiomEdit based?

BiomEdit is headquartered in Greenfield, United States, in the North America region.

How does BiomEdit make money?

Two revenue lines are on record. Biologics (Animal Health) is the primary driver. The others are feed Additives (Foundational Products).

Who are BiomEdit's main competitors?

Broad incumbents on record are Elanco Animal Health, Zoetis, Merck Animal Health, Phibro Animal Health, Novozymes (Novonesis), dsm-firmenich Animal Nutrition & Health and Cargill Animal Nutrition. Direct peers are Arm & Hammer Animal and Food Production, Chr. Hansen and Kemin Industries.

Does BiomEdit have an API?

No public API is recorded for BiomEdit.

What industry is BiomEdit in?

BiomEdit's product category is Animal Health Biologics. Its primary akta.pro industry code is HLAAAFAL, Non-Human Microbiome Therapeutics (veterinary/animal microbiome interventions), with a secondary code of HLAMAHAH, Nutraceuticals & Functional Ingredients for Animal Diets (Probiotics, Omega-3, Joint, GI). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Inside Indiana BusinessBiomEdit ready to advance development of first commercial product after initial approval - Inside INdiana BusinessBiomEdit received conditional licensure for its engineered probiotic product from the USDA, aiming to treat necrotic enteritis in chickens. The product has reduced chicken deaths by 50% and is being trialed by 35 million chickens. The company expects full licensure and a branded sale under Optavant after meeting additional requirements.PR NewswireBiomEdit's First-of-its-Kind Engineered Bacterial Biologic for Poultry Receives Conditional Licensure from USDABiomEdit's CPerf LLV, an engineered bacterial biologic for poultry, received USDA conditional licensure after demonstrating a 48.7% reduction in necrotic enteritis-associated mortality in broilers. The product, expected to be branded Optavant, will undergo commercial evaluation with three U.S. poultry producers. BiomEdit plans to advance toward full licensure.Pulse 2.0BiomEdit Acquires Folium Science To Expand Programmable Veterinary BiologicsBiomEdit, an animal health biotechnology company, has acquired Folium Science's technology platform and pipeline assets, including BiomElix One, a poultry feed additive approved in Brazil. Terms were not disclosed. The deal adds Folium's Guided Biotics CRISPR-Cas technology to BiomEdit's Programmable Veterinary Biologics platform, giving it two poultry programs, with lead candidate BE-101 in final conditional licensure stages.AgnavigatorBiologicals for animal health: BiomEdit readies dual Brazil launch for 2027 following Folium acquisitionBiomEdit acquired Folium Science to add CRISPR-Cas technology and a feed additive, planning two Brazil launches in 2027. The deal includes BiomElix One, a CRISPR-based E. coli strain approved by Brazil's MAPA. The company expects U.S. licensure for BE-101 this quarter and a Series C round in Q1 2026.Inside Indiana BusinessBiomEdit acquires England-based company’s technology and pipeline assets - Inside INdiana BusinessIndianapolis-based BiomEdit, a startup spun out of Elanco Animal Health in 2022, announced Tuesday it has acquired England-based Folium Science's technology platform and pipeline assets, with terms undisclosed. The deal adds Folium's poultry feed additive BiomElix One, approved in Brazil, and its Guided Biotics CRISPR-Cas technology. BiomEdit's first product, BE-101, expected to be Optavant, is due later this year after USDA licensure.BiomeditBiomEdit Acquires Folium Science Technology and Pipeline Assets to Expand Programmable Veterinary Biologics CapabilitiesBiomEdit acquired Folium Science's technology platform and pipeline assets, including BiomElix One, a poultry feed additive approved in Brazil. The deal adds CRISPR-based microbiome technology to BiomEdit's programmable veterinary biologics, expanding its pipeline. Terms were not disclosed.citybizBiomEdit Acquires Folium Science Assets to Expand Veterinary Biologics PipelineBiomEdit acquired Folium Science's technology platform and pipeline assets, including an approved poultry feed additive and CRISPR-based microbiome technology. The deal adds BiomElix One, approved by Brazil's MAPA, and Guided Biotics CRISPR-Cas to its portfolio. The acquisition expands BiomEdit's poultry pipeline and precision microbiome capabilities.PR NewswireBiomEdit Acquires Folium Science Technology and Pipeline Assets to Expand Programmable Veterinary Biologics CapabilitiesBiomEdit acquired Folium Science's technology platform and pipeline assets, including BiomElix One, a poultry feed additive approved in Brazil. The deal adds CRISPR-based microbiome technology to BiomEdit's programmable veterinary biologics, expanding its pipeline. Terms were not disclosed.indexPurdue Innovates, Boilermaker innovation win big at 2026 TechPoint Mira AwardsPurdue University's innovation ecosystem was prominently recognized at TechPoint's 2026 Mira Awards, which celebrate Indiana's tech sector, with Purdue Innovates winning the Innovation Service Partner of the Year award and Purdue University President Mung Chiang named the 2026 Trailblazer. Several Purdue-connected companies secured awards including FiberX (AgBioscience Innovation Award), BiomEdit (Deal of the Year for its $18.6M Series B round with Elanco Animal Health as a lead investor), and a joint Talent Innovation Award recognizing a partnership including Eli Lilly and Company, Ivy Tech Community College, and Purdue University.AgtechnavigatorBetter guts, healthier chickens: BiomEdit seeks Series C funding to commercialize biologicalBiomEdit is preparing to raise a Series C to commercialize its probiotic BE-101 for treating necrotic enteritis in broiler chickens. The company expects conditional USDA licensure in Q3 2026 and commercial readiness by Q4 2026. Funding will also support treatments for other animals.